HMGCS2

Across TCGA pan-cancer cohorts, HMGCS2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated HMGCS2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HMGCS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HMGCS2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, LSCC, and COAD are the cancer types where HMGCS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.606	0.310	.001	52	view →
LSCC	DFS	Median	All	0.254	1.000	<.001	25	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.923	.033	24	view →
UCEC	OS	Tertile	III,IV	0.145	1.000	.024	12	view →
GBM	DFS	Median	All	0.358	0.855	.013	6	view →
CCRCC	DFS	Median	III,IV	0.145	0.774	.016	5	view →
LUAD	DFS	Median	All	0.893	1.000	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

HMGCS2–PDAC (OS)

Open the PDAC breakdown →